Boehringer trims Connecticut workforce as sales suffer

Struggling with falling sales, Boehringer Ingelheim is trimming its workforce in Connecticut, which accounts for about 2,700 staffers altogether. 

A company spokesperson tells FierceBiotech that less than 5% of its staff at the Ridgefield site is affected by the move, or 2% of the total, but the company is looking to find new positions for some of the people involved in the cutback. 

"Boehringer Ingelheim is in the process of rebalancing its workforce in the U.S. to put the company in the best position for future growth," the company says in a statement. 

The 294-acre Ridgefield campus is the site of one of three major R&D centers for Boehringer and serves as its U.S. headquarters. Boehringer announced plans for a $65 million facility to support R&D and production back in 2011.

Just weeks ago the company reviewed a possible move to sell its $2.3 billion generics unit and a facility in Columbus, OH. Last fall Boehringer also said it would trim hundreds of jobs in Germany to account for a 5% drop in sales and a reduced forecast for the second half of the year.

Suggested Articles

Moderna’s shares shrunk by nearly 5% before the long holiday weekend Thursday after a report out by Stat said the biotech was delaying its trial.

Keep your post-pandemic trials on track: learn how the right clinical supply chain partner can help sponsors avoid trial disruption. Read now>>

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.